Sight Sciences, Inc. SGHT
We take great care to ensure that the data presented and summarized in this overview for Sight Sciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SGHT
View all-
Kck Ltd. Tortola, D84.37MShares$31.1 Million100.0% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR3.19MShares$22.7 Million0.41% of portfolio
-
Black Rock Inc. New York, NY2.12MShares$15.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.91MShares$13.6 Million0.0% of portfolio
-
Americana Partners, LLC Houston, TX1.23MShares$8.74 Million0.14% of portfolio
-
B Group, Inc. Dallas, TX930KShares$6.61 Million2.35% of portfolio
-
Geode Capital Management, LLC Boston, MA853KShares$6.07 Million0.0% of portfolio
-
Apollo Management Holdings, L.P. New York, NY672KShares$4.77 Million0.05% of portfolio
-
State Street Corp Boston, MA664KShares$4.72 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA476KShares$3.39 Million0.0% of portfolio
Latest Institutional Activity in SGHT
Top Purchases
Top Sells
About SGHT
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Insider Transactions at SGHT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 02
2025
|
James Rodberg Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,518
-1.56%
|
$20,144
$8.25 P/Share
|
|
Nov 25
2025
|
Jeremy B. Hayden Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
44,850
-14.88%
|
$358,800
$8.08 P/Share
|
|
Nov 25
2025
|
Jeremy B. Hayden Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
44,850
+6.84%
|
$44,850
$1.96 P/Share
|
|
Nov 17
2025
|
Brenton Taylor EVP, Operations & R&D |
SELL
Open market or private sale
|
Direct |
14,418
-7.78%
|
$100,926
$7.06 P/Share
|
|
Nov 12
2025
|
Jeremy B. Hayden Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,150
-1.21%
|
$25,200
$8.01 P/Share
|
|
Nov 12
2025
|
Jeremy B. Hayden Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,150
+0.6%
|
$3,150
$1.96 P/Share
|
|
Nov 11
2025
|
Alison Bauerlein Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,006
+3.58%
|
-
|
|
Nov 11
2025
|
James Rodberg Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,337
+8.68%
|
-
|
|
Oct 06
2025
|
Brenton Taylor EVP, Operations & R&D |
SELL
Open market or private sale
|
Direct |
591
-0.32%
|
$1,773
$3.37 P/Share
|
|
Oct 03
2025
|
Jeremy B. Hayden Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
9,731
-3.65%
|
$29,193
$3.27 P/Share
|
|
Oct 03
2025
|
David Badawi Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
6,033
-0.32%
|
$18,099
$3.27 P/Share
|
|
Oct 02
2025
|
Alison Bauerlein Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
19,948
-3.23%
|
$59,844
$3.3 P/Share
|
|
Oct 01
2025
|
Paul Badawi President and CEO |
SELL
Open market or private sale
|
Direct |
24,441
-0.41%
|
$73,323
$3.34 P/Share
|
|
Sep 11
2025
|
Catherine Mazzacco |
SELL
Bona fide gift
|
Direct |
37,492
-47.76%
|
-
|
|
Sep 02
2025
|
Brenton Taylor EVP, Operations & R&D |
BUY
Grant, award, or other acquisition
|
Direct |
25,840
+12.21%
|
-
|
|
Jul 17
2025
|
David Badawi Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+2.09%
|
$0
$0.12 P/Share
|
|
Jul 03
2025
|
Jeremy B. Hayden Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
9,160
-3.33%
|
$36,640
$4.17 P/Share
|
|
Jul 03
2025
|
David Badawi Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
5,679
-0.31%
|
$22,716
$4.17 P/Share
|
|
Jul 02
2025
|
Alison Bauerlein Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
19,260
-3.02%
|
$77,040
$4.1 P/Share
|
|
Jul 02
2025
|
Matthew Link Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,889
-0.58%
|
$19,556
$4.1 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.42M shares |
|---|---|
| Other acquisition or disposition | 513K shares |
| Open market or private purchase | 337K shares |
| Exercise of conversion of derivative security | 88K shares |
| Open market or private sale | 338K shares |
|---|---|
| Payment of exercise price or tax liability | 12K shares |
| Bona fide gift | 37.5K shares |